6,622 Shares in Corteva, Inc. $CTVA Purchased by Rice Hall James & Associates LLC

Rice Hall James & Associates LLC purchased a new stake in Corteva, Inc. (NYSE:CTVA) during the first quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 6,622 shares of the company’s stock, valued at approximately $554,000.

A number of other hedge funds have also recently made changes to their positions in the stock. Vanguard Group Inc. increased its holdings in Corteva by 0.4% in the 4th quarter. Vanguard Group Inc. now owns 80,536,951 shares of the company’s stock valued at $5,398,392,000 after purchasing an additional 317,538 shares during the last quarter. State Street Corp boosted its position in shares of Corteva by 3.7% during the fourth quarter. State Street Corp now owns 36,570,876 shares of the company’s stock worth $2,451,346,000 after buying an additional 1,290,071 shares during the period. Franklin Resources Inc. boosted its position in shares of Corteva by 4.3% during the fourth quarter. Franklin Resources Inc. now owns 19,537,500 shares of the company’s stock worth $1,309,599,000 after buying an additional 805,873 shares during the period. Harris Associates L P grew its stake in shares of Corteva by 168.1% in the fourth quarter. Harris Associates L P now owns 17,026,221 shares of the company’s stock valued at $1,141,268,000 after buying an additional 10,675,052 shares in the last quarter. Finally, Northern Trust Corp raised its holdings in shares of Corteva by 5.0% in the 4th quarter. Northern Trust Corp now owns 11,731,834 shares of the company’s stock valued at $786,385,000 after buying an additional 562,550 shares during the period. Hedge funds and other institutional investors own 81.54% of the company’s stock.

Corteva Price Performance

Shares of NYSE CTVA opened at $89.23 on Monday. The stock’s 50-day moving average is $81.39 and its two-hundred day moving average is $78.99. The company has a debt-to-equity ratio of 0.07, a current ratio of 1.47 and a quick ratio of 1.03. The company has a market cap of $59.68 billion, a price-to-earnings ratio of 52.49, a price-to-earnings-growth ratio of 2.70 and a beta of 0.56. Corteva, Inc. has a 1-year low of $60.53 and a 1-year high of $89.39.

Corteva (NYSE:CTVA) last released its quarterly earnings data on Tuesday, May 5th. The company reported $1.50 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.18 by $0.32. The business had revenue of $4.91 billion during the quarter, compared to analysts’ expectations of $4.64 billion. Corteva had a net margin of 6.50% and a return on equity of 9.95%. The company’s revenue for the quarter was up 11.0% on a year-over-year basis. During the same period in the previous year, the company earned $1.13 EPS. Corteva has set its FY 2026 guidance at 3.450-3.700 EPS. Analysts forecast that Corteva, Inc. will post 3.76 EPS for the current fiscal year.

Corteva Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 15th. Shareholders of record on Tuesday, September 1st will be given a dividend of $0.18 per share. The ex-dividend date of this dividend is Tuesday, September 1st. This represents a $0.72 annualized dividend and a yield of 0.8%. Corteva’s payout ratio is 42.35%.

Analysts Set New Price Targets

CTVA has been the topic of several research reports. The Goldman Sachs Group increased their target price on Corteva from $88.00 to $96.00 and gave the stock a “buy” rating in a research note on Tuesday, April 14th. BNP Paribas Exane boosted their price target on shares of Corteva from $74.00 to $77.00 in a research note on Wednesday, May 6th. Barclays raised their price objective on shares of Corteva from $84.00 to $91.00 and gave the company an “overweight” rating in a research note on Thursday, June 11th. Deutsche Bank Aktiengesellschaft lifted their price objective on shares of Corteva from $90.00 to $100.00 in a report on Monday, May 11th. Finally, Royal Bank Of Canada increased their target price on shares of Corteva from $97.00 to $103.00 and gave the stock an “outperform” rating in a report on Tuesday, July 21st. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and eight have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $90.19.

Key Stories Impacting Corteva

Here are the key news stories impacting Corteva this week:

• Positive Sentiment: Oppenheimer raised its price target on Corteva to $95 from $89 and kept an “outperform” rating, signaling confidence in further upside for the stock.
• Positive Sentiment: Zacks upgraded Corteva to Rank #2 (Buy), citing improving earnings prospects ahead of the company’s upcoming results.
• Positive Sentiment: Analysts expect Q2 earnings growth as premium seed demand, new products, and productivity gains help offset pricing and inflation pressure. Corteva Set to Report Q2 Earnings: What Investors Should Expect
• Neutral Sentiment: Corteva declared a quarterly dividend of $0.18 per share, payable September 15 to shareholders of record on September 1, which supports the stock’s income profile but is not a major growth catalyst. Corteva Declares Quarterly Dividend
• Neutral Sentiment: The company is set to report Q2 earnings soon, and investors are awaiting confirmation that demand and operating efficiency trends are holding up. Corteva (CTVA) Projected to Release Quarterly Earnings on Thursday

About Corteva

Corteva, Inc (NYSE: CTVA) is an independent global agriculture company that was established as a publicly traded firm in mid‑2019 following the separation of the agriculture businesses from DowDuPont. The company focuses on delivering technologies and products that help farmers increase productivity and manage crop health. Corteva’s operations combine seed genetics, crop protection chemistries, digital tools and biological solutions to address the full cycle of crop production.

Core business activities include research and development of seed genetics and trait technologies, formulation and sale of crop protection products (such as herbicides, insecticides and fungicides), and the development of seed treatments and biologicals.